Celcuity/$CELC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Celcuity
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Ticker
$CELC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
87
ISIN
US15102K1007
Website
Celcuity Metrics
BasicAdvanced
$455M
-
-$3.04
0.56
-
Price and volume
Market cap
$455M
Beta
0.56
52-week high
$19.77
52-week low
$7.58
Average daily volume
143K
Financial strength
Current ratio
6.61
Quick ratio
6.248
Long term debt to equity
113.698
Total debt to equity
113.893
Interest coverage (TTM)
-10.52%
Profitability
EBITDA (TTM)
-126.774
Management effectiveness
Return on assets (TTM)
-39.04%
Return on equity (TTM)
-115.39%
Valuation
Price to book
5.24
Price to tangible book (TTM)
5.24
Price to free cash flow (TTM)
-4.9
Free cash flow yield (TTM)
-20.41%
Free cash flow per share (TTM)
-245.09%
Growth
Earnings per share change (TTM)
10.40%
3-year earnings per share growth (CAGR)
7.88%
What the Analysts think about Celcuity
Analyst ratings (Buy, Hold, Sell) for Celcuity stock.
Bulls say / Bears say
Celcuity's lead candidate, gedatolisib, is advancing through Phase 3 clinical trials for HR+/HER2- advanced breast cancer, with top-line data expected in 2025, potentially leading to significant market opportunities. (nasdaq.com)
Institutional investors, including the New York State Common Retirement Fund and Barclays PLC, have significantly increased their stakes in Celcuity, indicating strong confidence in the company's prospects. (etfdailynews.com, marketbeat.com)
Analysts from Needham & Company LLC and HC Wainwright have reiterated 'buy' ratings for Celcuity, with price targets of $29.00 and $27.00 respectively, suggesting potential upside from current levels. (techdows.com, marketbeat.com)
Celcuity reported a net loss of $63.8 million for the full year 2023, with a Q4 net loss of $18.8 million, reflecting increased R&D expenses and raising concerns about financial sustainability. (gurufocus.com)
The company's Q4 2024 earnings per share of ($0.85) missed consensus estimates by $0.13, indicating potential challenges in meeting financial expectations. (marketbeat.com)
Despite ongoing clinical trials, Celcuity has yet to generate revenue, relying heavily on cash reserves and financing activities, which may pose risks if clinical outcomes are delayed or unfavorable. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Celcuity Financial Performance
Revenues and expenses
Celcuity Earnings Performance
Company profitability
Celcuity News
AllArticlesVideos
Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences
GlobeNewsWire·1 month ago
Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewsWire·1 month ago
Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Celcuity stock?
Celcuity (CELC) has a market cap of $455M as of June 28, 2025.
What is the P/E ratio for Celcuity stock?
The price to earnings (P/E) ratio for Celcuity (CELC) stock is 0 as of June 28, 2025.
Does Celcuity stock pay dividends?
No, Celcuity (CELC) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Celcuity dividend payment date?
Celcuity (CELC) stock does not pay dividends to its shareholders.
What is the beta indicator for Celcuity?
Celcuity (CELC) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.